Brad Goodman, MD
Allergy & Immunology · Savannah, GANPI 1407816432
Payments from drug & device makers
Across 622 payments — averaging $2090.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$423K
- Sanofi US Services Inc.$184K
- Teva Pharmaceuticals USA, Inc.$144K
- GSK$111K
- Sanofi$73K
- Hikma Pharmaceuticals USA$73K
- plus $292K from 32 others
Across 56 payments — averaging $739.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glenmark Pharmaceuticals Inc., USA$26K
- Ichnos Glenmark Innovation Inc$15K
- LEO Pharma AS$250
What the payments were for
- Food & beverage$4,65398%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 61 | $422,724 |
| Sanofi US Services Inc. | 53 | $184,334 |
| Teva Pharmaceuticals USA, Inc. | 64 | $143,590 |
| GSK | 52 | $111,130 |
| Sanofi | 33 | $73,398 |
| Hikma Pharmaceuticals USA | 7 | $73,246 |
| AstraZeneca | 27 | $55,178 |
| VYNE Pharmaceuticals Inc. | 1 | $50,850 |
| Bristol Myers Squibb | 2 | $49,621 |
| Cipla USA Inc. | 13 | $40,072 |
| AbbVie | 11 | $31,395 |
| Astrazeneca AB | 4 | $27,717 |
| Dermavant Sciences, Inc. | 149 | $25,686 |
| E.r. Squibb & Sons, L.L.C. | 2 | $7,666 |
| Octapharma USA, Inc. | 19 | $969 |
| Regeneron Healthcare Solutions, Inc. | 18 | $452 |
| Medtronic | 13 | $332 |
| Pfizer | 18 | $304 |
| Amgen(2 entities) | 7 | $242 |
| Spinal Simplicity, LLC | 1 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $193 |
| Genentech USA, Inc. | 9 | $175 |
| Grifols USA, LLC | 7 | $157 |
| Alk-abello, Inc | 9 | $151 |
| Novartis | 7 | $145 |
| CSL Behring | 4 | $112 |
| Pharming Healthcare, Inc. | 6 | $105 |
| Trice Medical, Inc. | 1 | $80 |
| Kaleo, Inc. | 5 | $80 |
| Hospira, Inc. | 2 | $38 |
| Merck | 2 | $33 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| LEO Pharma Inc. | 1 | $20 |
| USWM, LLC | 1 | $18 |
| Organon | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$230
- HA MINUTEMAN G3-R$196
- Accurian$124
How this compares
$1,300,490 in reported general payments places this provider in the 95th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $19,486 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $11,384 |
| Ipratropium Bromide | 202 | $9,372 |
| Epinephrine | 21 | $4,219 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $2,732 |
| Levocetirizine Dihydrochloride | 66 | $2,117 |
| Azelastine Hcl | 53 | $1,914 |
| Montelukast Sodium | 82 | $1,140 |
| Famotidine | 33 | $735 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $391 |
| Fluticasone Propionate | 24 | $316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $279 |
| Prednisone | 17 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $157 | $19,48614 claims |
| GSKBreo Ellipta | $111,130 | $11,38432 claims |
| Hikma Pharmaceuticals USAEpinephrine | $73,246 | $4,21921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Savannah
- Bruce FinkelSavannah$277K
- Wasil KhanSavannah$7K
- Monica KenneySavannah$5K
- Nathan SegallStockbridge$4.5M
- Tracy BridgesAlbany$1.5M
- Michael BlaissRoswell$1.1M
- Robert ChrzanowskiColumbus$941K
- Stanley FinemanMarietta$855K
- Robert CartwrightColumbus$678K
- Deborah BirxAtlanta$470K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.